Syndax Pharmaceuticals (SNDX) Change in Accured Expenses (2015 - 2026)

Syndax Pharmaceuticals' Change in Accured Expenses history runs 12 years deep, the most recent figure standing at -$28.3 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 1019.19% year-over-year to -$28.3 million; the TTM figure through Mar 2026 stood at $16.4 million (down 29.87% YoY), while the FY2025 annual figure was $42.2 million, up 120.32% from the prior year.
• Change in Accured Expenses was -$28.3 million for Q1 2026 at Syndax Pharmaceuticals, down from $25.7 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $25.7 million in Q4 2025 to a low of -$28.3 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged $3.4 million across 5 years, with a median of $2.4 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Change in Accured Expenses jumped 9304.88% in 2022, then tumbled 1019.19% in 2026.
• A 5-year view of Change in Accured Expenses shows it stood at $11.0 million in 2022, then plunged by 31.58% to $7.5 million in 2023, then soared by 55.34% to $11.7 million in 2024, then soared by 120.46% to $25.7 million in 2025, then slumped by 210.33% to -$28.3 million in 2026.
• The last three Change in Accured Expenses figures came in at -$28.3 million (Q1 2026), $25.7 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.